Cogent Biosciences, Inc. (NASDAQ:COGT) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Cogent Biosciences, Inc. (NASDAQ:COGT) have been given a consensus rating of “Moderate Buy” by the fourteen brokerages that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, nine have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $43.4545.

Several analysts have recently commented on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Cogent Biosciences in a research report on Monday, December 8th. JPMorgan Chase & Co. boosted their price target on shares of Cogent Biosciences to $67.00 and gave the company an “overweight” rating in a research note on Friday, December 19th. Jefferies Financial Group assumed coverage on shares of Cogent Biosciences in a research report on Monday, March 16th. They set a “buy” rating and a $55.00 price objective for the company. HC Wainwright lifted their target price on shares of Cogent Biosciences to $52.00 and gave the company a “buy” rating in a report on Tuesday, January 6th. Finally, Robert W. Baird set a $35.00 target price on Cogent Biosciences in a research report on Thursday, February 19th.

Insider Transactions at Cogent Biosciences

In related news, insider Evan Kearns sold 65,000 shares of the business’s stock in a transaction on Friday, December 26th. The stock was sold at an average price of $38.70, for a total value of $2,515,500.00. Following the sale, the insider owned 109,398 shares in the company, valued at approximately $4,233,702.60. The trade was a 37.27% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider John Edward Robinson sold 90,000 shares of Cogent Biosciences stock in a transaction dated Friday, December 26th. The shares were sold at an average price of $38.74, for a total value of $3,486,600.00. Following the completion of the transaction, the insider directly owned 140,002 shares of the company’s stock, valued at approximately $5,423,677.48. This represents a 39.13% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 3,737,642 shares of company stock worth $136,600,345 over the last quarter. 7.29% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Cogent Biosciences

Hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its position in Cogent Biosciences by 48.4% in the 4th quarter. Vanguard Group Inc. now owns 11,514,326 shares of the technology company’s stock valued at $408,989,000 after buying an additional 3,756,664 shares during the period. Deerfield Management Company L.P. increased its position in shares of Cogent Biosciences by 242.9% during the third quarter. Deerfield Management Company L.P. now owns 9,053,118 shares of the technology company’s stock worth $130,003,000 after acquiring an additional 6,412,903 shares during the period. Fairmount Funds Management LLC increased its position in shares of Cogent Biosciences by 44.6% during the third quarter. Fairmount Funds Management LLC now owns 9,003,418 shares of the technology company’s stock worth $129,289,000 after acquiring an additional 2,777,777 shares during the period. RTW Investments LP raised its stake in shares of Cogent Biosciences by 119.0% in the fourth quarter. RTW Investments LP now owns 7,592,241 shares of the technology company’s stock valued at $269,676,000 after acquiring an additional 4,124,755 shares in the last quarter. Finally, Commodore Capital LP raised its stake in shares of Cogent Biosciences by 213.7% in the third quarter. Commodore Capital LP now owns 7,250,000 shares of the technology company’s stock valued at $104,110,000 after acquiring an additional 4,938,836 shares in the last quarter.

Cogent Biosciences Price Performance

COGT stock opened at $33.38 on Friday. Cogent Biosciences has a 1 year low of $3.72 and a 1 year high of $43.73. The firm has a market capitalization of $5.42 billion, a PE ratio of -15.45 and a beta of 0.47. The company has a debt-to-equity ratio of 0.41, a current ratio of 14.23 and a quick ratio of 14.23. The business has a 50 day simple moving average of $37.26 and a 200-day simple moving average of $29.71.

Cogent Biosciences (NASDAQ:COGT) last issued its earnings results on Tuesday, February 17th. The technology company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). Equities research analysts anticipate that Cogent Biosciences will post -2.42 earnings per share for the current fiscal year.

Key Headlines Impacting Cogent Biosciences

Here are the key news stories impacting Cogent Biosciences this week:

• Positive Sentiment: HC Wainwright remains constructive — the firm keeps a “Buy” rating and a $52 price target on COGT, which supports upside expectations despite model changes. HC Wainwright Note
• Positive Sentiment: Wedbush reiterated an “Outperform” rating, signaling continued analyst confidence that could limit downside and attract risk‑tolerant investors. Wedbush Reiterates Outperform
• Positive Sentiment: Recent analyst coverage included a $42.82 consensus price target from brokerages, giving a clear reference point for upside from current levels. Price Target Note
• Neutral Sentiment: Short‑interest reports show anomalous values (reported as 0 shares with NaN changes and 0.0 days‑to‑cover), indicating either no material short exposure or a data/reporting issue — not currently a clear driver.
• Negative Sentiment: Boone Capital sold 945,042 shares in Q4, reducing its position value by about $13.6M — a meaningful institutional sale that can weigh on the stock, particularly in the near term. Boone Capital Sale
• Negative Sentiment: HC Wainwright trimmed EPS forecasts for multiple 2026 quarters and lowered FY2026 estimates (they still maintain a Buy), which implies weaker near‑term profitability expectations and is a likely contributor to selling pressure. HC Wainwright Estimates

About Cogent Biosciences

Cogent Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments.

The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors.